List of Excipients in Branded Drug MONOKET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	MONOKET	isosorbide mononitrate	62175-361	ALUMINUM STEARATE
Lannett Company Inc	MONOKET	isosorbide mononitrate	62175-361	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	MONOKET	isosorbide mononitrate	62175-361	LACTOSE
Lannett Company Inc	MONOKET	isosorbide mononitrate	62175-361	SILICON DIOXIDE
Lannett Company Inc	MONOKET	isosorbide mononitrate	62175-361	TALC

Monoket Excipient Strategy and Commercial Opportunities for Isosorbide Mononitrate

Last updated: August 22, 2026

Monoket is an oral isosorbide mononitrate immediate-release tablet used for angina prophylaxis. Its commercial value is driven by low-cost generic supply, manufacturing efficiency, dose flexibility, and potential reformulation rather than by active-ingredient exclusivity. The strongest excipient strategy is a simple, robust tablet platform using well-established compendial excipients, with separate development paths for immediate-release generics, modified-release products, and differentiated low-dose or adherence-oriented presentations.

What is Monoket and which drug products compete with it?

Monoket contains isosorbide mononitrate, an organic nitrate that produces vasodilation through nitric-oxide-mediated mechanisms. The product is administered orally for prevention of angina attacks and is not intended for acute relief of an ongoing attack because its onset is not sufficiently rapid for that use.[1]

The core competitive products are:

Product	Active ingredient	Dosage form	Typical commercial position
Monoket	Isosorbide mononitrate	Immediate-release tablet	Legacy branded product and reference for generic positioning
Generic isosorbide mononitrate	Isosorbide mononitrate	Immediate-release tablet	Low-cost multisource market
Imdur	Isosorbide mononitrate	Extended-release tablet	Modified-release branded and generic competition
ISMO	Isosorbide mononitrate	Immediate-release tablet	Historical branded competitor
Isosorbide dinitrate products	Isosorbide dinitrate	Immediate-release and sublingual products	Therapeutic alternative, with different pharmacokinetics

Monoket and Imdur should not be treated as interchangeable formulation targets. Monoket is an immediate-release product, while Imdur uses an extended-release design. A generic Monoket strategy should focus on bioequivalence to the relevant immediate-release reference product. An Imdur strategy requires a separate release-control platform, dissolution profile, and clinical bridging assessment.

What excipients are used in Monoket tablets?

Public product information identifies conventional tablet excipients for Monoket, including lactose, starch, microcrystalline cellulose, and magnesium stearate, although exact composition can vary by strength, market, manufacturer, and historical product version.[1,2]

The likely functional architecture is:

Excipient class	Typical function in an isosorbide mononitrate tablet
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Binder, dry-binder, and disintegration-support excipient
Maize or pregelatinized starch	Binder and disintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide, where used	Glidant and powder-flow aid
Film-coating polymers, where used	Appearance, handling, moisture protection, and swallowability

The commercially important point is that Monoket does not require an exotic excipient system. A generic developer can usually pursue a conventional, compendial formulation with a manageable formulation-development burden. The main technical risks are blend uniformity, tablet strength, rapid disintegration, dissolution consistency, nitrate stability, and dose-to-dose manufacturing reproducibility.

Exact excipient composition should be established from the applicable reference-product labeling, FDA inactive-ingredient records, and the target-market product dossier. Historical labels should not be assumed to describe the current commercial formulation.

How should an excipient strategy be designed for generic Monoket?

A practical development strategy is to begin with a direct-compression or dry-granulation platform. Isosorbide mononitrate is a relatively high-dose active pharmaceutical ingredient in common tablet strengths, so the formulation must provide adequate powder flow and compressibility without creating excessive tablet mass.

Recommended immediate-release platform

A candidate platform can use:

• Lactose monohydrate as the principal diluent.
• Microcrystalline cellulose to improve compactibility and tablet mechanical strength.
• Starch or pregelatinized starch to support disintegration.
• Magnesium stearate at a controlled concentration and blending time.
• Colloidal silicon dioxide only where powder flow requires improvement.
• A thin film coat where branding, swallowability, moisture control, or handling characteristics justify the added process step.

The formulation should avoid unnecessary excipient complexity. Each additional excipient increases supplier qualification, analytical method requirements, extractables and leachables assessment, and potential regulatory questions.

Direct compression versus granulation

Direct compression has the lowest process cost and is attractive for a mature, price-sensitive product. It also limits water exposure, which may reduce stability risk for a nitrate-containing active.

Dry granulation can improve flow and content uniformity when the active or excipient blend has poor flow. It adds roller-compaction and milling steps but avoids the water and drying cycle associated with wet granulation.

Wet granulation is less attractive unless development data show a clear need for improved content uniformity, compressibility, or tablet robustness. The process creates a higher validation burden and can affect solid-state behavior, residual moisture, and dissolution.

Which excipients create the largest regulatory and commercial risks?

The main risks are not patent-related. They are tied to safety, tolerability, manufacturing consistency, and bioequivalence.

Lactose and carbohydrate intolerance

Lactose is a commercially efficient filler, but its presence may require clear labeling for patients with lactose intolerance or rare hereditary galactose disorders, depending on the jurisdiction and amount per dose. A lactose-free formulation using microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient could create a modest differentiation point.

That opportunity is limited. Most purchasers of generic isosorbide mononitrate prioritize price, supply reliability, and pharmacy substitution status over lactose avoidance. A lactose-free product is more likely to support institutional contracting or specialty-channel differentiation than a broad price premium.

Magnesium stearate and dissolution

Excessive lubrication or prolonged blending with magnesium stearate can reduce tablet wetting and slow dissolution. The formulation should control lubricant concentration, lubricant grade, blend time, and shear exposure. Dissolution development should evaluate sensitivity to these process variables rather than treating magnesium stearate as a fixed, low-risk ingredient.

Colorants and allergen concerns

A color-free tablet can reduce formulation complexity and eliminate certain patient or market objections. The benefit is mainly operational and labeling-related. Colorants may still help product identification across strengths, which reduces dispensing errors. The optimal decision depends on the manufacturer’s packaging and human-factors strategy.

Nitrosamine and impurity control

Isosorbide mononitrate is an organic nitrate, but the presence of nitrate functionality does not by itself establish a nitrosamine impurity problem. A risk assessment should examine nitrate-related degradation, process impurities, nitrite sources, amine-containing excipients, water quality, packaging components, and supplier-specific impurities under FDA’s nitrosamine guidance.[3]

The formulation should use qualified excipients with controlled nitrite and amine impurity profiles where relevant. Stability studies should include assay, related substances, dissolution, water content, and tablet physical properties.

What formulations are protected by patents?

Monoket’s immediate-release tablet platform is unlikely to support a meaningful modern patent moat based solely on conventional excipients. The active ingredient is an established generic drug, and standard lactose-starch-cellulose-magnesium-stearate formulations generally do not create commercially durable exclusivity.

Potential patentable subject matter could include:

Patent area	Potential value
Modified-release matrix	Moderate to high if release performance is distinctive and clinically useful
Osmotic or multiparticulate delivery	Potentially high, but development cost is greater
Low-dose or split-dose presentation	Usually modest unless tied to a clinically differentiated regimen
Taste-masked or orally disintegrating tablet	Limited for an adult antiangina product, but possible for swallowing-related needs
Moisture-protective packaging	Usually better protected as know-how or trade dress than as a strong composition patent
New polymorph or particle-size control	Potential value only if it improves manufacturability or bioavailability
Combination therapy	Potentially valuable, but requires clinical and regulatory support
Abuse-deterrent or controlled-release design	Usually weak commercial fit for this drug

The strongest opportunity would be a modified-release or adherence-oriented product with demonstrable clinical or pharmacokinetic advantages. A new excipient combination alone would face obviousness and enablement challenges unless it produced an unexpected dissolution, stability, or bioavailability result.

When does Monoket lose exclusivity?

Monoket is a legacy product. Its principal active-ingredient, formulation, and market-exclusivity periods are historical rather than current commercial barriers. Generic entry is already established for isosorbide mononitrate immediate-release tablets.

The relevant U.S. exclusivity framework is therefore:

Exclusivity element	Current strategic relevance
Original NDA exclusivity	Expired
New chemical entity exclusivity	Expired
Conventional composition patents	Not a current barrier to ordinary generic entry
Formulation patents	Relevant only to specific modified-release or differentiated products
Method-of-use patents	Potentially relevant only if listed, enforceable, and not carved out
ANDA approval	Main pathway for a conventional generic
Paragraph IV challenge	Relevant only if an unexpired listed patent remains in the Orange Book

The FDA Orange Book should be reviewed for the specific reference-listed drug and active listed patents before filing or acquisition. A product-level conclusion should not be based on Monoket’s historical brand identity alone.[4]

What is the Orange Book status of Monoket?

The Orange Book identifies approved prescription drug products, therapeutic equivalence evaluations, patent information, and certain exclusivity data. For a conventional immediate-release isosorbide mononitrate tablet, the key commercial question is whether an active reference-listed drug remains eligible for ANDA comparison and whether any unexpired patents or exclusivities are listed against that product.[4]

A generic developer should confirm:

1. The current reference-listed drug.
2. The applicable strength and dosage form.
3. Whether the reference product is currently marketed.
4. Therapeutic-equivalence codes for approved generic products.
5. Any listed patents and their expiration dates.
6. Whether a Paragraph IV certification would be necessary.
7. Whether a suitability petition or 505(b)(2) pathway is more appropriate for a non-equivalent formulation.

For a standard immediate-release generic with no relevant unexpired listed patent, the principal risk is regulatory and commercial execution rather than patent litigation.

Are Paragraph IV challenges or litigation likely?

Paragraph IV litigation risk appears limited for a mature immediate-release isosorbide mononitrate product unless a newer formulation patent is listed against the target reference product. Paragraph IV certification can still arise where a listed patent remains active, but the strategic value of challenging a weak, low-price product may be limited by expected market erosion and litigation cost.

The more relevant disputes would involve:

• Whether a proposed modified-release product falls within a formulation claim.
• Whether a manufacturing process infringes a process patent.
• Whether a 505(b)(2) product relies on a protected clinical or pharmacokinetic profile.
• Whether a method-of-use patent can be carved out through labeling.
• Whether a product is therapeutically equivalent to the reference listed drug.

No major current Monoket-specific settlement or litigation event should be assumed without a targeted review of FDA records, district-court dockets, Patent Trial and Appeal Board proceedings, and assignment databases.

What commercial opportunities exist for Monoket excipient innovation?

The market is mature and price-sensitive, but several opportunities remain.

1. Low-cost, high-reliability generic supply

The most credible opportunity is operational. A manufacturer can compete through:

• Low tablet cost.
• High line efficiency.
• Reliable API and excipient sourcing.
• Low complaint rates.
• Consistent dissolution.
• Strong supply continuity.
• Packaging that protects against moisture without excessive cost.

For a mature cardiovascular generic, supply reliability can be more valuable than a minor formulation distinction.

2. Lactose-free and simplified-label products

A lactose-free tablet can support hospital, long-term-care, and selected retail channels. The opportunity is commercially narrow but easy to communicate if the formulation remains bioequivalent and cost competitive.

A simplified, color-free product can reduce excipient-related labeling and manufacturing complexity. The tradeoff is less visual differentiation between strengths.

3. Modified-release isosorbide mononitrate

Modified release offers a larger commercial opportunity than simple excipient substitution. The product could target once-daily dosing, smoother exposure, or improved adherence. The technical burden is substantial:

• Release must remain consistent across strengths.
• Dose dumping must be excluded.
• Food effects must be characterized.
• Alcohol-induced release changes must be assessed where relevant.
• Pharmacokinetic bioequivalence may require a more complex study.
• The product may follow an NDA, 505(b)(2), or other jurisdiction-specific pathway rather than a simple ANDA.

Imdur and generic extended-release products create a crowded comparator set, so any new product needs a clear cost or adherence advantage.

4. Alternative dosage forms

Orally disintegrating tablets, mini-tablets, or liquid formulations could address swallowing difficulty. The patient population is primarily adult and chronic-use, so the commercial case is narrower than for pediatric drugs. Liquid products also introduce stability, packaging, dosing-device, and preservative issues.

Sublingual delivery would move the product toward a different clinical use and pharmacokinetic profile. It should not be treated as a simple excipient modification of Monoket.

How strong is the patent estate for Monoket?

The patent estate is weak for conventional immediate-release generic competition and potentially stronger only for new delivery systems.

Estate component	Relative strength
Isosorbide mononitrate active ingredient	Weak because of long-established generic availability
Conventional tablet excipients	Weak
Immediate-release manufacturing process	Usually weak unless unusually specific and difficult to design around
Extended-release formulation	Moderate to strong if claims are technically narrow and clinically supported
Novel delivery device	Moderate, depending on implementation
Method of use	Variable and often vulnerable to label carve-outs
Packaging and moisture protection	Usually weak as patent protection; stronger as know-how

Freedom-to-operate work should focus on extended-release patents, coating systems, matrix polymers, osmotic technologies, and any patents covering the reference product’s pharmacokinetic profile. The conventional Monoket tablet is unlikely to justify a large patent-acquisition premium.

What generic entry risks exist for Monoket?

Generic entry risk is already realized rather than prospective. The relevant commercial risks for a new entrant are:

• Low net pricing from multiple approved suppliers.
• Pharmacy substitution and formulary pressure.
• API price volatility.
• Shortages caused by single-source excipient or packaging components.
• Failure to match dissolution despite acceptable assay results.
• Product recalls caused by blend uniformity or tablet defects.
• Difficulty securing sufficient volume to offset registration and launch costs.
• Limited differentiation in a mature therapeutic category.

A new entrant should model a low-price, multisource scenario rather than a branded-generic scenario. The business case depends on scale, manufacturing utilization, and portfolio synergies with other cardiovascular tablets.

How does Monoket compare with Imdur?

Monoket and Imdur have different formulation and commercial profiles.

Factor	Monoket	Imdur
Release profile	Immediate release	Extended release
Main development route for generic	Conventional ANDA-style equivalence	More complex modified-release equivalence
Excipient strategy	Diluent, binder, disintegrant, lubricant	Release-controlling matrix or coating system
Technical burden	Low to moderate	Moderate to high
Patent opportunity	Limited	Greater potential around release technology
Differentiation potential	Low	Higher
Manufacturing cost	Generally lower	Generally higher
Commercial risk	Price erosion	Development and bioequivalence risk

The best investment target depends on the objective. Immediate-release Monoket is suitable for efficient generic manufacturing. Extended-release isosorbide mononitrate offers more product differentiation but carries greater regulatory and patent exposure.

Key Takeaways

• Monoket is an established immediate-release isosorbide mononitrate tablet with limited current exclusivity value.
• A conventional excipient system based on lactose or a lactose-free diluent, microcrystalline cellulose, starch, and magnesium stearate is technically appropriate.
• Formulation development should prioritize dissolution, blend uniformity, tablet robustness, stability, and low manufacturing cost.
• The strongest commercial opportunity is reliable, low-cost generic supply, not a conventional excipient patent.
• Lactose-free, color-free, or adherence-oriented products offer modest differentiation.
• Modified-release delivery provides greater patent and commercial potential but requires a substantially more complex development and regulatory strategy.
• Orange Book, FDA labeling, DailyMed, and current court records must be reviewed for product-specific patent and approval status.
• Biosimilar risk is not applicable because isosorbide mononitrate is a small-molecule drug, not a biologic.
• A new entrant should assume severe price competition and evaluate the product as part of a broader generic cardiovascular portfolio.

FAQs

Is Monoket a biologic or biosimilar product?

No. Monoket contains the small-molecule drug isosorbide mononitrate. Biosimilar rules do not apply. Generic applicants generally use an abbreviated drug-approval pathway based on pharmaceutical equivalence and bioequivalence.

Can a lactose-free Monoket generic obtain patent protection?

A lactose-free composition alone would usually provide weak patent differentiation. Stronger protection would require a non-obvious formulation with demonstrated advantages in stability, dissolution, bioavailability, tolerability, or manufacturing performance.

Which excipient is most likely to affect isosorbide mononitrate dissolution?

Magnesium stearate is a key process variable because excessive lubrication or overblending can reduce wetting and slow dissolution. Disintegrant type, compression force, and tablet porosity are also important.

Is an extended-release isosorbide mononitrate product eligible for a simple ANDA?

Not necessarily. The regulatory route depends on the reference product, release mechanism, formulation differences, and FDA determinations. A modified-release product may require more complex equivalence work or a 505(b)(2) application.

Does Monoket have meaningful revenue exposure for an originator company?

The legacy Monoket brand is unlikely to have material exclusivity-driven revenue exposure because immediate-release isosorbide mononitrate is a mature generic market. Commercial value is more likely to reside in manufacturing scale, supply contracts, or differentiated modified-release products.

References

1. U.S. Food and Drug Administration. (n.d.). Monoket (isosorbide mononitrate) tablets prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Isosorbide mononitrate tablet drug labeling.
3. U.S. Food and Drug Administration. (2023). Guidance for industry: Control of nitrosamine impurities in human drugs.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.